258 related articles for article (PubMed ID: 22532266)
1. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers.
Abu-Hejleh T; Mezhir JJ; Goodheart MJ; Halfdanarson TR
Curr Oncol Rep; 2012 Aug; 14(4):277-84. PubMed ID: 22532266
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab-induced bowel perforation.
Sliesoraitis S; Tawfik B
J Am Osteopath Assoc; 2011 Jul; 111(7):437-41. PubMed ID: 21803880
[TBL] [Abstract][Full Text] [Related]
3. [Surgical management of bevacizumab-associated peritonitis due to perforation].
Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal perforation due to bevacizumab in colorectal cancer.
Saif MW; Elfiky A; Salem RR
Ann Surg Oncol; 2007 Jun; 14(6):1860-9. PubMed ID: 17356952
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab-induced hypertension: pathogenesis and management.
Syrigos KN; Karapanagiotou E; Boura P; Manegold C; Harrington K
BioDrugs; 2011 Jun; 25(3):159-69. PubMed ID: 21627340
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients.
Borofsky SE; Levine MS; Rubesin SE; Tanyi JL; Chu CS; Lev-Toaff AS
Abdom Imaging; 2013 Apr; 38(2):265-72. PubMed ID: 22627832
[TBL] [Abstract][Full Text] [Related]
7. Infusion of bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated.
Borzomati D; Nappo G; Valeri S; Vincenzi B; Ripetti V; Coppola R
Updates Surg; 2013 Jun; 65(2):121-4. PubMed ID: 23532741
[TBL] [Abstract][Full Text] [Related]
8. Bowel perforation in non-small cell lung cancer after bevacizumab therapy.
Schellhaas E; Loddenkemper C; Schmittel A; Buhr HJ; Pohlen U
Invest New Drugs; 2009 Apr; 27(2):184-7. PubMed ID: 18665327
[TBL] [Abstract][Full Text] [Related]
9. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?
Eskens FA; Sleijfer S
Eur J Cancer; 2008 Nov; 44(16):2350-6. PubMed ID: 18789679
[TBL] [Abstract][Full Text] [Related]
10. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
Han ES; Monk BJ
Gynecol Oncol; 2007 Apr; 105(1):3-6. PubMed ID: 17383545
[No Abstract] [Full Text] [Related]
11. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
12. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
de Gramont A; Van Cutsem E
Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
[TBL] [Abstract][Full Text] [Related]
13. Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab.
Gray J; Murren J; Sharma A; Kelley S; Detterbeck F; Bepler G
J Thorac Oncol; 2007 Jun; 2(6):571-3. PubMed ID: 17545855
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation.
Tol J; Cats A; Mol L; Koopman M; Bos MM; van der Hoeven JJ; Antonini NF; van Krieken JH; Punt CJ
Invest New Drugs; 2008 Aug; 26(4):393-7. PubMed ID: 18335169
[TBL] [Abstract][Full Text] [Related]
15. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
16. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
Heinzerling JH; Huerta S
Curr Surg; 2006; 63(5):334-7. PubMed ID: 16971205
[TBL] [Abstract][Full Text] [Related]
17. Treatment of bevacizumab-induced hypertension by amlodipine.
Mir O; Coriat R; Ropert S; Cabanes L; Blanchet B; Camps S; Billemont B; Knebelmann B; Goldwasser F
Invest New Drugs; 2012 Apr; 30(2):702-7. PubMed ID: 20878444
[TBL] [Abstract][Full Text] [Related]
18. Endoscopic management of colonic perforation owing to angiogenesis inhibitors.
Ezzedine S; Bege T; Berdah S; Vitton V; Grimaud JC; Barthet M
Surg Laparosc Endosc Percutan Tech; 2010 Dec; 20(6):e230-2. PubMed ID: 21150409
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab: antiangiogenic cancer therapy.
Culy C
Drugs Today (Barc); 2005 Jan; 41(1):23-36. PubMed ID: 15753967
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups.
Qi WX; Shen Z; Tang LN; Yao Y
Eur J Clin Pharmacol; 2014 Aug; 70(8):893-906. PubMed ID: 24858820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]